Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Gastroenterology. 2015 May 28;149(3):705–717.e2. doi: 10.1053/j.gastro.2015.05.042

Figure 5.

Figure 5

Imatinib inhibits the growth of colon cancers. A) POP77 was grown in Matrigel as organoids. Size of imatinib-treated organoids decreased in a dose-dependent manner (n = 10 organoids/group; mean ± SE shown). B) Photomicroscopy of representative POP77 organoids showing loss of smooth organoid borders and accumulation of membranous blebs with increasing imatinib dose (bar = 100 μm). C) 8×105 DLD1 cells were injected into the flanks of NSG mice and treated with imatinib or saline vehicle for 10 days. Tumors were weighed at post-injection day 10 (n = 4 tumors/group; mean ± SE shown). D) Chunks of UMCOLON-#8-luc were implanted subcutaneously into mice and mice were treated with imatinib or saline vehicle for 14 days. Tumor bioluminescence flux was recorded and natural log transformation and linear regression was performed (n = 21 tumors for vehicle, n = 16 tumors for imatinib; mean ± SE shown). E) Representative bioluminescent images shown. *, P < 0.05 in Student t test.